Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Inclusion Criteria:

• Confirmed relapsed ovarian cancer.
• Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).
• One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.
• At least three weeks since prior chemotherapy and recovery from any related toxicities.
• At least four weeks since prior radiotherapy and recovery from any related toxicities.